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Limited organ availability and prolonged waiting periodsfor donor hearts has led to the increased use of ventric-ular assist devices (VADs) as a bridge to transplanta-tion. Recognition of potential myocardial recovery in
some reversible cardiac diseases has prompted the use of these
devices as a bridge to recovery. Extracorporeal membrane oxy-
genation is often the only choice for circulatory support in infants
and smaller children.1 There are currently no pulsatile VADs
approved for use in infants and children in the United States.2
Adult devices such as the Thoratec VAD (Pleasanton, Calif) have
been used in some children as a bridge to transplantation.3-5
However, the discrepancy in size between the device and the
patient limits its use, particularly if bridge to recovery and removal
of the device are planned.
Clinical Summary
An 11-year-old previously healthy girl was noted by her grand-
mother to have an “irregular heartbeat” associated with gasping
and agonal respirations while sleeping. Cardiopulmonary resusci-
tation was initiated, and emergency medical services were called.
Ventricular fibrillation was detected and successfully cardioverted
to sinus rhythm. After transport to a local hospital, the patient was
transferred to The Children’s Hospital of Philadelphia. Refractory
polymorphic ventricular tachycardia resulted in hypotension and
low cardiac output. A lidocaine infusion was begun with poor
control of the ventricular ectopy. Echocardiography revealed mod-
erate left ventricular dysfunction with a shortening fraction of 19%
and moderate mitral regurgitation. Right ventricular function was
preserved. Initiation of inotropic drug therapy resulted in increased
ectopy and further deterioration. Because of the isolated left ven-
tricular dysfunction, she was a candidate for left ventricular assist
device (LVAD) support.
The patient was taken to the operating room for insertion of a
Thoratec LVAD. After cardiopulmonary bypass was initiated, the
inflow cannula was positioned in the ventricular apex. An alterna-
tive technique would be the use of atrial cannulation for VAD
inflow; however, filling of the VAD may be improved with use of
apical cannulation. The outflow graft (14 mm) was anastomosed to
the ascending aorta. The conduits were de-aired and connected to
the device. The patient was weaned from bypass with the device in
the volume mode, but later it was converted to the fixed rate mode
secondary to inadequate filling of the VAD. The early postopera-
tive course was significant for right ventricular dysfunction requir-
ing aggressive volume resuscitation and support with inotropic
drug therapy to optimize preload to the VAD. Amiodarone therapy
was initiated because of refractory ventricular ectopy. She was
extubated on postoperative day 2. A heparin infusion was used for
anticoagulation with no bleeding complications. Mild hemolysis
was the only device-related morbidity. Serial echocardiograms
demonstrated complete recovery of ventricular function.
The VAD was removed after 13 days of support. The patient
was placed on cardiopulmonary bypass. The outflow cannula was
stapled with a vascular stapler and divided at the aorta. The
cannula was removed from the left ventricular apex, leaving the
sewing ring, which was approximated using pledgetted 0 sutures.
After the patient was separated from cardiopulmonary bypass,
transesophageal echocardiography demonstrated normal ventricu-
lar function. Because of persistent ventricular ectopy, despite
amiodarone therapy, she underwent implantation of a transvenous
defibrillator (internal cardioverter-defibrillator). She was subse-
quently transitioned to mexiletine therapy. An echocardiogram
performed 5 months after discharge demonstrated normal ventric-
ular function. At that time, she had no cardiovascular symptoms.
Recurrent ventricular fibrillation has been detected by the internal
cardioverter-defibrillator. The cause of the polymorphic ventricu-
lar arrhythmia has not been determined.
Discussion
The largest experience with pulsatile VADs in children is in
Europe. The Berlin Heart (Berlin, Germany) and the MEDOS
(Stolberg, Germany) assist devices are available in a variety of
sizes, are suitable for all age groups, and have been used success-
fully as bridge to recovery and transplant. Neither the Berlin Heart
nor the MEDOS VAD are available in the United States, and no
pulsatile device is currently approved for use in pediatric patients.
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The Thoratec VAD has been used in a small number of children
according to the manufacturer’s database. As of May 2003, the
Thoratec VAD had been used as a bridge to transplant in the
United States in 8 children weighing less than 30 kg, but it had not
been used in any children as a bridge to recovery. The smallest
child was 17 kg.5 Unlike extracorporeal membrane oxygenation,
during the period of VAD support patients can be extubated and
ambulate, allowing rehabilitation. There is no single solution for
pediatric patients requiring mechanical support, but carefully se-
lected pediatric patients may benefit from the Thoratec device as a
bridge to transplant recovery. The current case demonstrates that,
even in a relatively small child, the device can be removed without
adverse effects on ventricular function despite apical cannulation.
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The bovine jugular vein conduit for right ventricular outflow tract
reconstruction: A feasible alternative to homograft conduits?
Tomaso Bottio, MD, PhD,a Gaetano Thiene, MD,b Vladimiro Vida, MD,a Mila Della Barbera, MD,b Annalisa Angelini, MD,b
Giovanni Stellin, MD,a and Gino Gerosa, MD,a Padua, Italy
The bovine jugular vein conduit (BJVC) has been pro-posed for use in cardiac surgery for correction of con-genital heart defects, either for right ventricular outflowtract (RVOT) reconstruction1 or total cavopulmonary
anastomosis completion in Fontan circulation.2 Short-term and
midterm results with the BJVC are controversial: satisfactory
when used for RVOT reconstruction but rather disappointing for
Fontan completion. In this study we report our early and late
clinical results with BJVCs implanted in infants and children for
RVOT reconstruction.
Clinical Summary
Between June 1999 and December 2002, 10 patients (7 male and
3 female patients) with a median age of 2 months (mean age, 13.7
 25.1 months) underwent surgical repair of congenital heart
defects, including reconstruction of the RVOT with a BJVC (Con-
tegra; Medtronic, Inc, Minneapolis, Minn).
Patient demographics are detailed in Table 1.3 Truncus arteri-
osus was the indication in 5 patients (with right ventricular hyp-
oplasia in 1 patient), tetralogy of Fallot with pulmonary atresia in
2 patients, aortic arch interruption type B with severe aortic ste-
nosis in 1 patient, double-outlet right ventricle with pulmonary
atresia in 1 patient, and aortic stenosis in 1 patient. Four patients
had undergone previous palliative procedures.
Results
There were 2 (20%) hospital deaths. One patient (patient 3) oper-
ated on for truncus arteriosus died suddenly on the 52nd postop-
erative day at home. The second patient (patient 5), who under-
went a Ross-Konno procedure and a mitral valvuloplasty for aortic
and mitral stenosis, died on the first postoperative day after an
airway suction procedure. A third patient (patient 8), a baby girl
operated on for truncus arteriosus type A-4 of Van Praagh classi-
fication, died of respiratory distress syndrome on the 20th postop-
erative day after extracorporeal membrane oxygenator assistance.
Postmortem examination was performed in patients 3 and 5.
The remaining 7 patients were alive at the last follow-up.
Echocardiographic data, recorded after a median time of 25
months (mean time, 24.3  14 months), showed trivial incompe-
tence of the BJVC in 3 patients and moderate incompetence in 1
patient. A transvalvular vein conduit peak gradient of greater than
30 mm Hg was observed in 2 patients. In 1 patient a peak gradient
of greater than 30 mm Hg was detected at the level of the distal
anastomosis between the conduit and the left pulmonary artery.
Morphologic investigation was performed in an unimplanted
conduit that served as a control (Figure 1) and in the 2 conduits
explanted at autopsy (Figure 2).
The unimplanted conduit showed a well-fixed tissue with leaf-
lets consisting of a compact layer of collagen (fibrosa) and a layer
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